Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 3, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details a specific transaction on May 1, 2006, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 817,279 Ordinary Shares. These shares were transferred on behalf of participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of these transactions on May 3, 2006.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or risk factors. It notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—are noted as having an interest in the shares held in the GSK Trust in the same capacity as other employees. The notification complies with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Transaction Date: May 1, 2006.
- Shares Transferred: 817,279 Ordinary Shares.
- Entity Involved: Abacus (GSK) Trustees Limited (GSK Trust).
- Plan Reference: SmithKline Beecham Employee Share Option Plan 1991.
- Directors with Interest: Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop.
- Notification Date: May 3, 2006.